Clinical Trials Logo

Clinical Trial Summary

This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.


Clinical Trial Description

n/a


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01445262
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date February 2011
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT01949051 - A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis Phase 2
Completed NCT01957202 - A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) Phase 2
Completed NCT01962467 - A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine Phase 1
Completed NCT01001130 - Regulatory AVAMYS Nasal Spray PMS N/A
Completed NCT01622283 - Pharmacokinetic Study of Levocetirizine Oral Solution Phase 1
Completed NCT02397915 - Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays Phase 4
Completed NCT01916226 - A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Phase 4
Completed NCT00109486 - Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray Phase 3